Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
On September 10, 2021, Cellectis reported its share and voting rights data as of August 31, 2021. The company had a total of 45,465,310 shares in capital and 51,067,217 voting rights. Cellectis is a gene editing company specializing in CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment. With over 21 years of expertise, it uses its TALEN® technology and PulseAgile system for therapeutic advancements. Cellectis aims to address blood disorders and cancers, enhancing its product pipeline.
Cellectis S.A. (NASDAQ: CLLS) announced its participation in five upcoming virtual investor conferences taking place between September 7 and September 15, 2021. The conferences include the Annual Biotech Symposium by Goldman Sachs, Citi’s Biopharma Conference, Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and Baird Global Healthcare Conference. The live webcasts will be accessible on the Company’s investor webpage. Cellectis focuses on gene editing and immunotherapies aimed at treating various cancers and monogenic diseases, utilizing TALEN technology and an allogeneic approach.
Cellectis S.A. (NASDAQ: CLLS) announced preliminary positive data for UCARTCS1, a potential therapy for relapsed or refractory multiple myeloma, during the ASGCT 24th annual meeting. The company has completed successful training runs at its GMP facilities and disclosed new preclinical programs targeting various cancers and genetic diseases. As of June 30, 2021, Cellectis holds $257 million in cash, providing a runway into early 2023. However, the company reported a net loss of $40 million in Q2 2021, compared to $32 million in Q2 2020, highlighting financial challenges amid development efforts.
Cellectis, a gene editing company listed on Nasdaq under the ticker CLLS, announced its share statistics as of July 31, 2021. The total number of shares in circulation is 45,465,310, while the total voting rights amount to 51,535,159. The company focuses on developing innovative CAR-T immunotherapies for oncology, utilizing their TALEN® gene editing technology and PulseAgile system. Cellectis aims to offer off-the-shelf gene-edited CAR T-cells and is dedicated to treating various cancers through its UCART product candidates.
Cellectis S.A. (NASDAQ: CLLS) announced it will release its financial results for Q2 and H1 2021 on August 6, 2021, after U.S. market close. A conference call will follow at 8:00 AM NY time, with dial-in numbers provided. The company specializes in genome editing and developing CAR-T cell therapies for cancer treatment. Cellectis aims to meet unmet medical needs through its innovative products and technologies, including its TALEN® genome editing and PulseAgile electroporation systems. The notice emphasizes Cellectis’ ongoing commitment to advancing therapies for patients.
Cellectis S.A. (NASDAQ: CLLS) will report its Q2 2021 and six-month financial results on August 5, 2021, after US market close. This will be followed by a conference call on August 6, 2021, at 8 AM EDT. Cellectis focuses on gene editing and CAR-T immunotherapies, aiming to develop off-the-shelf therapeutics for cancer. Their UCART products target various cancers and they are advancing their HEAL platform for blood disorders. The company is headquartered in Paris and has operations in New York and Raleigh.
Cellectis, a pioneering gene editing company, has reported a total of 45,461,310 shares and 51,531,339 voting rights as of June 30, 2021. The company is focused on developing innovative CAR-T immunotherapies for cancer treatment and therapeutic gene editing for various diseases. With over 21 years of expertise, Cellectis utilizes its proprietary technologies to advance hematological malignancies and blood disorders. It operates from its headquarters in Paris and additional locations in New York and Raleigh, with listings on both Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis announced the development of four new product candidates targeting solid tumors, including UCART20x22, a bi-specific CAR-T cell therapy for B-cell malignancies, and others for mesothelin, MUC1, and cancer-associated fibroblasts. The new .HEAL platform aims to address genetic diseases like Sickle Cell Anemia and lysosomal storage disorders. Additionally, Cellectis is enhancing its GMP manufacturing capabilities to increase production independence and control over gene therapy processes. The company is advancing multiple clinical trials, achieving significant patient enrollment and early positive results.
Cellectis, a clinical-stage biopharmaceutical company, focuses on pioneering allogeneic CAR-T immunotherapies. As of May 31, 2021, the company reported a total of 45,461,310 shares in circulation and 51,531,739 voting rights. Cellectis aims to develop life-saving UCART product candidates for cancers like AML, B-ALL, and MM, leveraging its TALEN® gene editing technology. The company's headquarters are in Paris, with operational sites in New York and Raleigh. Cellectis is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis S.A. held its Annual Shareholders’ General Meeting on June 1, 2021, in Paris, with over 66% of voting rights exercised. Resolutions 1-24 passed, while Resolution 25 was rejected. The detailed voting results can be found on the company's website. Cellectis is pioneering allogeneic CAR-T therapies, focusing on off-the-shelf gene-edited CAR T-cells aimed at treating cancers like acute myeloid leukemia and multiple myeloma. The company is based in Paris, with additional offices in New York and Raleigh, and trades on Nasdaq under the symbol CLLS.